Your browser is no longer supported. Please, upgrade your browser.
Omeros Corporation
Index- P/E- EPS (ttm)-1.99 Insider Own3.20% Shs Outstand62.51M Perf Week-10.28%
Market Cap435.44M Forward P/E- EPS next Y-1.34 Insider Trans-3.61% Shs Float59.96M Perf Month10.12%
Income-123.70M PEG- EPS next Q-0.25 Inst Own49.40% Short Float19.15% Perf Quarter-54.94%
Sales90.50M P/S4.81 EPS this Y-41.50% Inst Trans-5.57% Short Ratio9.44 Perf Half Y-53.94%
Book/sh-4.20 P/B- EPS next Y30.70% ROA-80.90% Target Price34.80 Perf Year-39.78%
Cash/sh0.82 P/C8.64 EPS next 5Y- ROE58.10% 52W Range5.45 - 23.85 Perf YTD-50.51%
Dividend- P/FCF- EPS past 5Y-3.80% ROI-95.50% 52W High-70.36% Beta0.73
Dividend %- Quick Ratio2.10 Sales past 5Y40.40% Gross Margin98.90% 52W Low29.72% ATR0.47
Employees277 Current Ratio2.10 Sales Q/Q14.90% Oper. Margin- RSI (14)38.70 Volatility6.53% 6.51%
OptionableYes Debt/Eq- EPS Q/Q45.00% Profit Margin- Rel Volume0.46 Prev Close7.43
ShortableYes LT Debt/Eq- EarningsNov 09 AMC Payout- Avg Volume1.22M Price7.07
Recom2.00 SMA20-7.10% SMA50-19.82% SMA200-52.29% Volume553,553 Change-4.85%
Oct-08-21Downgrade JP Morgan Neutral → Underweight
Oct-01-21Downgrade Wedbush Neutral → Underperform
Oct-01-21Downgrade Maxim Group Buy → Hold
Sep-27-21Initiated JP Morgan Neutral $15
Feb-01-21Initiated UBS Buy $25
Oct-20-20Initiated BofA Securities Buy $21
Aug-21-20Reiterated H.C. Wainwright Buy $34 → $32
Aug-14-20Reiterated Maxim Group Buy $25 → $20
May-06-19Initiated Cantor Fitzgerald Overweight $26
Jul-12-18Initiated Seaport Global Securities Buy $30
Mar-23-18Downgrade Wedbush Outperform → Neutral $47 → $19
Mar-05-18Downgrade Needham Buy → Hold
Nov-08-17Initiated H.C. Wainwright Buy $30
May-11-17Downgrade Cantor Fitzgerald Buy → Neutral $21 → $15
Mar-17-17Reiterated Needham Buy $24 → $22
Mar-17-17Reiterated Maxim Group Buy $19 → $22
Nov-16-16Reiterated Wedbush Outperform $56 → $47
Nov-10-16Reiterated Needham Buy $28 → $24
Aug-10-16Reiterated Maxim Group Buy $30 → $19
Jun-03-16Initiated Cantor Fitzgerald Buy $21
Nov-09-21 06:25PM  
Nov-05-21 04:45PM  
Nov-04-21 10:53AM  
Nov-01-21 04:35PM  
Oct-31-21 06:19AM  
Oct-26-21 03:15PM  
Oct-21-21 10:00AM  
Oct-20-21 08:31AM  
Oct-18-21 05:39PM  
Oct-15-21 09:45PM  
Oct-13-21 06:40PM  
Oct-11-21 03:50PM  
Oct-07-21 10:30PM  
Oct-06-21 04:00PM  
Oct-05-21 06:32PM  
Oct-04-21 03:11PM  
Oct-03-21 08:51PM  
Oct-01-21 05:02PM  
Sep-30-21 08:36PM  
Aug-09-21 05:35PM  
Aug-03-21 08:30AM  
Aug-02-21 03:01PM  
Jun-14-21 12:45PM  
Jun-10-21 03:53PM  
Jun-09-21 05:00PM  
Jun-07-21 10:39PM  
Jun-05-21 08:01PM  
Jun-02-21 10:15PM  
Jun-01-21 05:05AM  
May-31-21 05:16PM  
May-29-21 10:29PM  
May-28-21 12:00PM  
May-27-21 10:08PM  
May-26-21 09:13AM  
May-22-21 10:48PM  
May-21-21 09:55AM  
May-20-21 02:40PM  
May-13-21 08:30AM  
May-10-21 05:55PM  
May-05-21 08:45AM  
May-04-21 05:45AM  
Mar-23-21 08:45AM  
Mar-01-21 05:25PM  
Feb-25-21 09:37AM  
Feb-03-21 05:30AM  
Jan-26-21 08:45AM  
Jan-19-21 08:30AM  
Jan-11-21 04:30PM  
Dec-15-20 11:42PM  
Dec-05-20 02:43AM  
Dec-03-20 07:30AM  
Dec-02-20 08:57AM  
Nov-18-20 09:00AM  
Nov-12-20 09:54AM  
Nov-09-20 05:45PM  
Nov-05-20 07:00AM  
Nov-03-20 12:31PM  
Oct-28-20 09:00AM  
Oct-22-20 08:00AM  
Oct-20-20 09:56AM  
Oct-16-20 08:30AM  
Oct-15-20 08:00AM  
Oct-01-20 09:00AM  
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and COVID-19; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consist of PPAR? (OMS405) to treat opioid and nicotine addiction; PDE7 (OMS527) for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HANISH ARNOLD CDirectorSep 08Option Exercise9.4410,00094,40010,000Sep 09 05:19 PM
Demopulos Gregory A MDCHAIRMAN, CEO & PRESIDENTJun 17Option Exercise4.1036,857151,1142,063,843Jun 17 08:30 PM
Demopulos Gregory A MDCHAIRMAN, CEO & PRESIDENTJun 17Sale14.9036,857549,1692,026,986Jun 17 08:30 PM
Demopulos Gregory A MDCHAIRMAN, CEO & PRESIDENTJun 15Option Exercise4.1036,856151,1102,063,842Jun 17 08:30 PM
Demopulos Gregory A MDCHAIRMAN, CEO & PRESIDENTJun 15Sale15.0236,856553,5772,026,986Jun 17 08:30 PM
Demopulos Gregory A MDCHAIRMAN, CEO & PRESIDENTApr 08Option Exercise4.1035,206144,3452,062,192Apr 08 07:52 PM
Demopulos Gregory A MDCHAIRMAN, CEO & PRESIDENTApr 08Sale17.7635,206625,2592,026,986Apr 08 07:52 PM
Demopulos Gregory A MDCHAIRMAN, CEO & PRESIDENTApr 07Option Exercise4.1037,407153,3692,064,393Apr 08 07:52 PM
Demopulos Gregory A MDCHAIRMAN, CEO & PRESIDENTApr 07Sale17.9137,407669,9592,026,986Apr 08 07:52 PM
JACOBSEN MICHAEL AVP FINANCE AND CAOFeb 22Option Exercise10.278,10083,18722,100Feb 23 05:20 PM
Demopulos Peter A MDDirectorFeb 22Option Exercise4.9210,00049,150198,516Feb 23 06:43 PM
JACOBSEN MICHAEL AVP FINANCE AND CAOFeb 22Sale23.288,100188,56814,000Feb 23 05:20 PM
JACOBSEN MICHAEL AVP FINANCE AND CAOFeb 19Option Exercise10.2710,000102,70024,000Feb 23 05:20 PM
JACOBSEN MICHAEL AVP FINANCE AND CAOFeb 19Sale22.6410,000226,40014,000Feb 23 05:20 PM
Hood Leroy E. MD PhDDirectorFeb 12Option Exercise4.535,00022,65074,390Feb 17 05:15 PM
JACOBSEN MICHAEL AVP FINANCE AND CAOFeb 10Option Exercise10.271,90019,51315,900Feb 12 05:05 PM
JACOBSEN MICHAEL AVP FINANCE AND CAOFeb 10Sale22.491,90042,73114,000Feb 12 05:05 PM
JACOBSEN MICHAEL AVP FINANCE AND CAOJan 20Option Exercise9.3710,00093,70014,000Jan 21 05:15 PM
JACOBSEN MICHAEL AVP FINANCE AND CAOJan 19Sale19.959,500189,5254,000Jan 21 05:15 PM
Cable Thomas J.DirectorJan 13Option Exercise4.535,00022,65040,067Jan 15 05:15 PM
Cable Thomas J.DirectorJan 13Sale16.975,00084,85035,067Jan 15 05:15 PM